Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Authors
Keywords
-
Journal
CLINICAL AND EXPERIMENTAL ALLERGY
Volume 51, Issue 7, Pages 915-931
Publisher
Wiley
Online
2021-05-26
DOI
10.1111/cea.13954
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
- (2021) William W Busse et al. Lancet Respiratory Medicine
- Mo1228 DUPILUMAB NORMALIZES THE EOSINOPHILIC ESOPHAGITIS DISEASE TRANSCRIPTOME IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
- (2020) Jennifer D. Hamilton et al. GASTROENTEROLOGY
- Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
- (2020) Ian D Pavord et al. Journal of Asthma and Allergy
- Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and SOLO 2)
- (2019) Diamant Thaçi et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study
- (2019) Jonathan Corren et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study
- (2019) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications
- (2019) Peter Capucilli et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis
- (2019) Jorge F. Maspero et al. Journal of Allergy and Clinical Immunology-In Practice
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
- (2019) Claus Bachert et al. LANCET
- Omalizumab for Atopic Dermatitis
- (2019) Ann Chen Wu JAMA Pediatrics
- Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
- (2019) Audrey Le Floc’h et al. ALLERGY
- Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
- (2019) Ikuo Hirano et al. GASTROENTEROLOGY
- Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
- (2018) William W. Busse et al. ADVANCES IN THERAPY
- IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy, and atopic dermatitis
- (2018) J. J. Heeringa et al. ALLERGY
- IgE repertoire and immunological memory: compartmental regulation and antibody function
- (2018) Hannah J Gould et al. INTERNATIONAL IMMUNOLOGY
- 1066 Biomarkers CCL17/TARC and total IgE do not predict clinical response to dupilumab in atopic dermatitis (AD): A post hoc analysis of pooled phase 3 data (SOLO 1 & 2)
- (2018) J.D. Hamilton et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
- (2018) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- (2018) Mario Castro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March
- (2018) David A. Hill et al. Journal of Allergy and Clinical Immunology-In Practice
- Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients
- (2018) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Hierarchical control of interleukin 13 (IL-13) signals in lung fibroblasts by STAT6 and SOX11
- (2018) Yasutaka Mitamura et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
- (2018) Karin Jonstam et al. ALLERGY
- Commonality of the IL-4/IL-13 pathway in atopic diseases
- (2017) Namita A. Gandhi et al. Expert Review of Clinical Immunology
- Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients
- (2017) Philip E. Silkoff et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- The Immunologic Mechanisms of Eosinophilic Esophagitis
- (2016) David A. Hill et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
- (2016) Claus Bachert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis
- (2015) Chao-Ying Gu et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Targeting key proximal drivers of type 2 inflammation in disease
- (2015) Namita A. Gandhi et al. NATURE REVIEWS DRUG DISCOVERY
- Eosinophilic Esophagitis
- (2015) Glenn T. Furuta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
- (2014) Jennifer D. Hamilton et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
- (2014) Lisa A. Beck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
- (2014) L. E. Macdonald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
- (2014) A. J. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis
- (2013) Bruce K. Tan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Targeting eosinophils in allergy, inflammation and beyond
- (2013) Patricia C. Fulkerson et al. NATURE REVIEWS DRUG DISCOVERY
- Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria
- (2011) Edyta Machura et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- Prevalence of Atopic Dermatitis, Allergic Rhinitis and Asthma in Taiwan: A National Study 2000 to 2007
- (2010) YT Chang et al. ACTA DERMATO-VENEREOLOGICA
- Untangling the Complex Web of IL-4- and IL-13-Mediated Signaling Pathways
- (2008) M. Wills-Karp et al. Science Signaling
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now